Developer docs
API playgroundTry for free, no card

Search company profiles

Demecan

Full company profile

uuid0002bw3

Namestring
Demecan
Legal namestring
DEMECAN Holding GmbH
Websiteurl
demecan.de
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Demecan is an independent German medical cannabis company founded in 2017 and headquartered in Ebersbach near Dresden. It operates the largest indoor medical cannabis production facility in Europe at the "Cannabis Campus," a former slaughterhouse acquired from Wayland in 2020 and progressively converted into EU-GMP-compliant cultivation and processing. The company is vertically integrated across the full value chain: cultivation under GACP standards, pharmaceutical-grade processing including proprietary Live Rosin cold-water extraction and solvent-free CO2 extraction, and direct distribution to German pharmacies via its own online shop (Fachbereich) and the herbery.de pharmacy platform, supported by a Frankfurt-based field sales team.

Its product portfolio comprises two main medical cannabis flower lines (CORE and CRAFT cultivars such as SKYGLOW, MAGISTER, SAXONIA, ICC, JM7, ECHO, and SUNSHINE PURE), the Oktonia extract line with six THC/CBD ratio variants, the FE 800 No. 1 Live Rosin extract, and the One concentrate 850 CO2 extract. Supporting digital services include the Patientenausweis digital patient ID card, an Apothekenfinder pharmacy locator, and the herbery.de SaaS pharmacy platform run by subsidiary Theranova Digital Solutions GmbH. Demecan sells exclusively to German pharmacies, which in turn dispense to patients on physician prescription, with statutory health insurance reimbursement available under certain conditions.

Commercially, Demecan generates revenue through wholesale flower and extract sales, imports from international producers to broaden its range, and laboratory/processing services to third parties. Pricing is not publicly disclosed and is shaped by pharmacy reimbursement mechanics. The company has secured two major regulatory milestones — the 2019 BfArM state cultivation contract as the only independent German producer, and the July 2024 MedCanG cultivation license as the first German recipient, which removed prior production caps — and has raised roughly €15M in 2022 and a high-seven-figure round at a ~€100M valuation in 2024 led by U.S.-based Trog Hawley Capital.

Short descriptiontext

Demecan is an independent German medical cannabis producer founded in 2017, vertically integrating EU-GMP cultivation, pharmaceutical extraction, and direct-to-pharmacy distribution from its Ebersbach facility near Dresden to German pharmacies and patients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersEbersbach An Der Fils, Germany
HQ citystring
Ebersbach An Der Fils
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical cannabis production, pharmaceutical cannabis cultivation, cannabis extract manufacturing, medical cannabis wholesale, EU-GMP cannabis processing
Industry3 codes
PRIMARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAGAG
Medical Cannabis Delivery & Online Ordering
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Delivery & Online Ordering Retail
SECONDARYCRANAFAG
Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
NAICS code3 codes
  • Medicinal and Botanical Manufacturing325411
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Drugs and Druggists' Sundries Merchant Wholesalers42421
SIC code3 codes
  • Medicinal Chemicals & Botanical Products2833
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Retail-Drug Stores And Proprietary Stores5912
Product category
Medical Cannabis
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1Medical Cannabis Flower Sales
TypeTransaction Fee
Description

Sale of medical cannabis flower products to pharmacies in Germany. Products include various strains with different THC/CBD profiles and terpenes.

demecan.de
2Medical Cannabis Extracts
TypeTransaction Fee
Description

Production and sale of cannabis extracts including Oktonia product line with various THC/CBD ratios for different therapeutic applications.

demecan.de
3Medical Cannabis Import
TypeTransaction Fee
Description

Import of medical cannabis from producers worldwide to expand product range and meet high-quality standards while complementing domestic production.

demecan.de
4Wholesale Distribution
TypeTransaction Fee
Description

Wholesale operations working with cannabis producers worldwide to ensure supply of medical cannabis to patients in Germany.

demecan.de
5Laboratory and Processing Services
TypeProfessional Services
Description

Laboratory and processing services related to medical cannabis offered to third parties, including processing of cannabis flowers at the Ebersbach facility.

demecan.de
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1Herbery.de
Description

Online pharmacy platform for medical cannabis distribution

demecan.de
+3 more records
Core offering1 text field

Demecan cultivates, manufactures, and distributes medical-grade cannabis flowers and extracts under EU-GMP pharmaceutical standards at its facility near Dresden, selling exclusively to German pharmacies through its Fachbereich online shop, field sales force, and herbery.de platform. The company operates the only fully independent, vertically integrated medical cannabis value chain in Germany — from cultivation through pharmaceutical processing to pharmacy delivery — with an annual production capacity of approximately 2 tons under its MedCanG cultivation license.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ~2 tons annual cannabis yield capacity
+2 more records
Product overview1 text field

DEMECAN is an independent German medical cannabis company covering the entire value chain from cultivation to pharmacy delivery. The product portfolio consists of medical cannabis flowers (CORE and CRAFT product lines with various cultivars and terpene profiles) and cannabis extracts (DEMECAN Oktonia product line including Typ1 extracts with calming effect and Typ2 extracts with stimulating effect, plus DEMECAN FE 800 and DEMECAN One concentrate). Supporting services include a digital patient ID card (DEMECAN Patientenausweis), an online pharmacy platform (herbery.de), and a pharmacy finder tool. The company operates from its production facility in Ebersbach near Dresden and sells exclusively to pharmacies.

Product and service1 record
1DEMECAN CORE Medical Cannabis Flowers
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Government agency that awarded DEMECAN the state contract in May 2019 as the only independent German company to cultivate medical cannabis in Germany. Continued regulatory oversight for medical cannabis production.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Federal Association of Pharmaceutical Cannabinoid Companies - DEMECAN is a member, contributing to industry advocacy and standards development.

3Bundesverband der Cannabiswirtschaft (BvCW)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Federal Association of the Cannabis Industry - DEMECAN is a member, contributing to industry advocacy.

demecan.de
4Association of Pharmacies Supplying Cannabis (VCA e.V.)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

DEMECAN is a supporting member of the Association of Pharmacies Supplying Cannabis.

demecan.de
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

Global law firm prepared a legal opinion for DEMECAN for a scientific cannabis pilot project in Germany, addressing EU and international law compliance for cannabis legalization.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Logistics partner involved in order fulfillment for pharmacy product distribution.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Shipping partner for product delivery to pharmacies in Germany, located in Weinheim.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Canadian licensed producer that has built European distribution including German medical cannabis. Comparable as another established import-source producer competing for shelf space and physician adoption in Germany.

TypeDirect peer
Description

Berlin-based German medical cannabis company also founded post-2017 to serve the domestic medical and emerging legal market. Directly comparable as a German-headquartered, vertically oriented cannabis operator with cultivation/processing ambitions and pharmacy-channel distribution.

TypeDirect peer
Description

Berlin-based medical cannabis company distributing imported cannabis flower and extracts to German pharmacies. Comparable as a direct Germany-focused medical cannabis distributor with a pharmacy-led GTM motion similar to DEMECAN's Fachbereich shop.

TypeBroad incumbent
Description

Global cannabis incumbent with prior German medical cannabis presence. Comparable as a large, multi-jurisdiction EU-GMP-certified producer whose import volumes compete with DEMECAN's domestic product in German pharmacy channels.

TypeDirect peer
Description

German B2B cannabis platform operating a pharmacy-facing ordering and distribution marketplace for medical cannabis. Comparable because it competes for the same German pharmacy relationships and serves the same prescriber/patient flow.

TypeBroad incumbent
Description

European medical cannabis operator with EU-GMP cultivation and distribution across multiple EU markets including Germany. Comparable as a multi-country producer/distributor targeting the same German pharmacy network.

7Bodhi+
TypeEmerging player
Description

Emerging European cannabis operator with German-market activity. Comparable as a smaller, niche European producer/distributor targeting the same medical cannabis pharmacy channel as DEMECAN.

TypeBroad incumbent
Description

Canadian-licensed global cannabis producer with significant European footprint including German operations. Comparable as a multi-jurisdiction producer competing with DEMECAN for the same German pharmacy/patient demand with imports.

9Tilray Brands
TypeBroad incumbent
Description

Large global cannabis operator with established EU-GMP-certified production in Portugal/Canada supplying the German medical market. Comparable as an international low-cost producer supplying German pharmacies via imports that compete directly with DEMECAN's domestic flower.

TypeEmerging player
Description

Cologne-based German medical cannabis startup focused on pharmacy distribution. Comparable as a smaller Germany-only competitor operating in the same pharmacy-prescriber ecosystem.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries4 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Demecan

Medical Cannabisdemecan.de

Demecan is an independent German medical cannabis producer founded in 2017, vertically integrating EU-GMP cultivation, pharmaceutical extraction, and direct-to-pharmacy distribution from its Ebersbach facility near Dresden to German pharmacies and patients.

What Demecan does

Demecan is an independent German medical cannabis company founded in 2017 and headquartered in Ebersbach near Dresden. It operates the largest indoor medical cannabis production facility in Europe at the "Cannabis Campus," a former slaughterhouse acquired from Wayland in 2020 and progressively converted into EU-GMP-compliant cultivation and processing. The company is vertically integrated across the full value chain: cultivation under GACP standards, pharmaceutical-grade processing including proprietary Live Rosin cold-water extraction and solvent-free CO2 extraction, and direct distribution to German pharmacies via its own online shop (Fachbereich) and the herbery.de pharmacy platform, supported by a Frankfurt-based field sales team.

Its product portfolio comprises two main medical cannabis flower lines (CORE and CRAFT cultivars such as SKYGLOW, MAGISTER, SAXONIA, ICC, JM7, ECHO, and SUNSHINE PURE), the Oktonia extract line with six THC/CBD ratio variants, the FE 800 No. 1 Live Rosin extract, and the One concentrate 850 CO2 extract. Supporting digital services include the Patientenausweis digital patient ID card, an Apothekenfinder pharmacy locator, and the herbery.de SaaS pharmacy platform run by subsidiary Theranova Digital Solutions GmbH. Demecan sells exclusively to German pharmacies, which in turn dispense to patients on physician prescription, with statutory health insurance reimbursement available under certain conditions.

Commercially, Demecan generates revenue through wholesale flower and extract sales, imports from international producers to broaden its range, and laboratory/processing services to third parties. Pricing is not publicly disclosed and is shaped by pharmacy reimbursement mechanics. The company has secured two major regulatory milestones — the 2019 BfArM state cultivation contract as the only independent German producer, and the July 2024 MedCanG cultivation license as the first German recipient, which removed prior production caps — and has raised roughly €15M in 2022 and a high-seven-figure round at a ~€100M valuation in 2024 led by U.S.-based Trog Hawley Capital.

Demecan firmographics

Firmographics
Name
Demecan
Legal name
DEMECAN Holding GmbH
Website
https://demecan.de
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
Demecan is an independent German medical cannabis producer founded in 2017, vertically integrating EU-GMP cultivation, pharmaceutical extraction, and direct-to-pharmacy distribution from its Ebersbach facility near Dresden to German pharmacies and patients.
Ownership category
akta.pro rank

Demecan industry classification

Industry
Product category
Medical Cannabis
NAICS
Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
SIC
Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Retail-Drug Stores And Proprietary Stores (5912)
akta.pro industry
PRIMARYCRANAFAB
Medical Cannabis Dispensaries
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)
SECONDARYCRANAGAG
Medical Cannabis Delivery & Online Ordering
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Delivery & Online Ordering Retail
SECONDARYCRANAFAG
Cannabis Dispensary + Delivery/Online Pickup (Omnichannel Retail)
Consumer Products & Retail/Tobacco, Alcohol & Cannabis Retail/Cannabis Dispensaries (Adult-Use & Medical)

Keywords

  • Medical cannabis production
  • Pharmaceutical cannabis cultivation
  • Cannabis extract manufacturing
  • Medical cannabis wholesale
  • EU-GMP cannabis processing

Where Demecan is headquartered

Location

Headquarters

HQ city
Ebersbach An Der Fils
HQ country
Germany
HQ region
Europe

Offices5 records

Markets served

Demecan business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Medical Cannabis Flower Sales: Sale of medical cannabis flower products to pharmacies in Germany. Products include various strains with different THC/CBD profiles and terpenes.
  2. Medical Cannabis Extracts: Production and sale of cannabis extracts including Oktonia product line with various THC/CBD ratios for different therapeutic applications.
  3. Medical Cannabis Import: Import of medical cannabis from producers worldwide to expand product range and meet high-quality standards while complementing domestic production.
  4. Wholesale Distribution: Wholesale operations working with cannabis producers worldwide to ensure supply of medical cannabis to patients in Germany.
  5. Laboratory and Processing Services: Laboratory and processing services related to medical cannabis offered to third parties, including processing of cannabis flowers at the Ebersbach facility.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Demecan product offering

Product offering

Core offering

Demecan cultivates, manufactures, and distributes medical-grade cannabis flowers and extracts under EU-GMP pharmaceutical standards at its facility near Dresden, selling exclusively to German pharmacies through its Fachbereich online shop, field sales force, and herbery.de platform. The company operates the only fully independent, vertically integrated medical cannabis value chain in Germany — from cultivation through pharmaceutical processing to pharmacy delivery — with an annual production capacity of approximately 2 tons under its MedCanG cultivation license.

Product overview

DEMECAN is an independent German medical cannabis company covering the entire value chain from cultivation to pharmacy delivery. The product portfolio consists of medical cannabis flowers (CORE and CRAFT product lines with various cultivars and terpene profiles) and cannabis extracts (DEMECAN Oktonia product line including Typ1 extracts with calming effect and Typ2 extracts with stimulating effect, plus DEMECAN FE 800 and DEMECAN One concentrate). Supporting services include a digital patient ID card (DEMECAN Patientenausweis), an online pharmacy platform (herbery.de), and a pharmacy finder tool. The company operates from its production facility in Ebersbach near Dresden and sells exclusively to pharmacies.

Differentiator

Problem solved

Functional benefit

Brands

  • Herbery.de: Online pharmacy platform for medical cannabis distribution
  • DEMECAN Wallet App
  • DEMECAN Patientenausweis
  • Cannabis Campus

Products and services

  • DEMECAN CORE Medical Cannabis Flowers

Quantifiable outcome

  • ~2 tons annual cannabis yield capacity
  • +2 more outcomes

Companies that use Demecan

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Demecan technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Demecan partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered core and minor.

  • Federal Institute for Drugs and Medical Devices (BfArM)coreStrategic or Co-development PartnerGovernment agency that awarded DEMECAN the state contract in May 2019 as the only independent German company to cultivate medical cannabis in Germany. Continued regulatory oversight for medical cannabis production.
  • Bundesverband pharmazeutischer Cannabinoidunternehmen (BPC)minorStrategic or Co-development PartnerFederal Association of Pharmaceutical Cannabinoid Companies - DEMECAN is a member, contributing to industry advocacy and standards development.
  • Bundesverband der Cannabiswirtschaft (BvCW)minorStrategic or Co-development PartnerFederal Association of the Cannabis Industry - DEMECAN is a member, contributing to industry advocacy.
  • Association of Pharmacies Supplying Cannabis (VCA e.V.)minorStrategic or Co-development PartnerDEMECAN is a supporting member of the Association of Pharmacies Supplying Cannabis.
  • DentonsminorImplementation/ SI/ Consulting PartnerGlobal law firm prepared a legal opinion for DEMECAN for a scientific cannabis pilot project in Germany, addressing EU and international law compliance for cannabis legalization.
  • MXP GmbHminorChannel Partner/ Reseller/ DistributorLogistics partner involved in order fulfillment for pharmacy product distribution.
  • trans-o-flex Express GmbH & Co. KGaAminorChannel Partner/ Reseller/ DistributorShipping partner for product delivery to pharmacies in Germany, located in Weinheim.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Demecan competitors and assessment

Company assessment

Broad incumbents

  • Organigram Holdings: Canadian licensed producer that has built European distribution including German medical cannabis. Comparable as another established import-source producer competing for shelf space and physician adoption in Germany.
  • Canopy Growth: Global cannabis incumbent with prior German medical cannabis presence. Comparable as a large, multi-jurisdiction EU-GMP-certified producer whose import volumes compete with DEMECAN's domestic product in German pharmacy channels.
  • Curaleaf International (formerly EMMAC Life Sciences): European medical cannabis operator with EU-GMP cultivation and distribution across multiple EU markets including Germany. Comparable as a multi-country producer/distributor targeting the same German pharmacy network.
  • Aurora Cannabis: Canadian-licensed global cannabis producer with significant European footprint including German operations. Comparable as a multi-jurisdiction producer competing with DEMECAN for the same German pharmacy/patient demand with imports.
  • Tilray Brands: Large global cannabis operator with established EU-GMP-certified production in Portugal/Canada supplying the German medical market. Comparable as an international low-cost producer supplying German pharmacies via imports that compete directly with DEMECAN's domestic flower.

Direct peers

  • Sanity Group: Berlin-based German medical cannabis company also founded post-2017 to serve the domestic medical and emerging legal market. Directly comparable as a German-headquartered, vertically oriented cannabis operator with cultivation/processing ambitions and pharmacy-channel distribution.
  • Cantourage: Berlin-based medical cannabis company distributing imported cannabis flower and extracts to German pharmacies. Comparable as a direct Germany-focused medical cannabis distributor with a pharmacy-led GTM motion similar to DEMECAN's Fachbereich shop.
  • Cansativa: German B2B cannabis platform operating a pharmacy-facing ordering and distribution marketplace for medical cannabis. Comparable because it competes for the same German pharmacy relationships and serves the same prescriber/patient flow.

Emerging players

  • Bodhi+: Emerging European cannabis operator with German-market activity. Comparable as a smaller, niche European producer/distributor targeting the same medical cannabis pharmacy channel as DEMECAN.
  • enua: Cologne-based German medical cannabis startup focused on pharmacy distribution. Comparable as a smaller Germany-only competitor operating in the same pharmacy-prescriber ecosystem.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Demecan social profiles

Digital presence

Demecan compliance and trust

Trust signal

Compliance3 records

Demecan financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Demecan leadership team

Management profile

Number of profiles

Profiles8 records

Demecan subsidiaries and ownership

Company hierarchy

Subsidiaries4 records

Demecan funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Demecan M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Demecan

What does Demecan do?

Demecan cultivates, manufactures, and distributes medical-grade cannabis flowers and extracts under EU-GMP pharmaceutical standards at its facility near Dresden, selling exclusively to German pharmacies through its Fachbereich online shop, field sales force, and herbery.de platform. The company operates the only fully independent, vertically integrated medical cannabis value chain in Germany — from cultivation through pharmaceutical processing to pharmacy delivery — with an annual production capacity of approximately 2 tons under its MedCanG cultivation license.

Is Demecan a public or private company?

Demecan is a private company. It is classified as venture growth investor backed and is currently operating.

When was Demecan founded?

Demecan was founded in 2017. It employs 51 to 100 people.

Where is Demecan based?

Demecan is headquartered in Ebersbach An Der Fils, Germany, in the Europe region.

How does Demecan make money?

Five revenue lines are on record. Medical Cannabis Flower Sales are the primary driver. The others are medical Cannabis Extracts, medical Cannabis Import, wholesale Distribution and laboratory and Processing Services.

Who are Demecan's main competitors?

Broad incumbents on record are Organigram Holdings, Canopy Growth, Curaleaf International (formerly EMMAC Life Sciences), Aurora Cannabis and Tilray Brands. Direct peers are Sanity Group, Cantourage and Cansativa. Emerging players are Bodhi+ and enua.

Does Demecan have an API?

No public API is recorded for Demecan.

What industry is Demecan in?

Demecan's product category is Medical Cannabis. Its primary akta.pro industry code is CRANAFAB, Medical Cannabis Dispensaries, with a secondary code of CRANAGAG, Medical Cannabis Delivery & Online Ordering. Its NAICS code is 325411 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StartbaseThe winners of the 2026 Saxony Startup Award have been announcedThe 2026 Saxony Startup Award was presented at the Innovation Conference in Dresden on June 17, honoring 116 applications. Winners include Oxaphil GmbH (Newcomer), Meliodays Medical (Startup), DEMECAN (Scale-up), and Elbklar (NextGen). The awards highlight Saxony's growing DeepTech and life sciences ecosystem.CannabisnowEurope’s Cannabis Market Is (Finally) Growing UpEurope's cannabis market is entering its investment era after years of uneven reform, as evidenced by events like the Talman House gathering at Berlin's Hotel Adlon Kempinski connecting founders from Zurich, Barcelona, Lisbon, and Warsaw with international investors. European operators are attracting global attention with pharmaceutical precision and regulatory stability while North America faces oversupply issues. Key developments include Germany's likely advancement of adult-use legalization, Demecan reaching a €100 million valuation, and cross-border consolidation expected to accelerate through 2026 as North American companies recognize Europe's potential.BenzingaThese 3 Cannabis Companies Hold Cultivation Licenses In Germany: A ~$1.8B Market Opportunity? - Aurora Cannabis (NASDAQ:ACB), Tilray Brands (NASDAQ:TLRY)Tilray, Aurora, and Demecan hold cultivation licenses in Germany's medical cannabis market, projected to reach €1.7 billion by 2025. Tilray operates Aphria RX, Aurora cultivates at its Leuna facility, and Demecan is the only fully German-owned cultivator. The companies aim to meet rising domestic demand and potentially export.KfgoCannabis producer Demecan nears 100-million-euro valuation after fresh funding, source saysDemecan Group, a German cannabis producer, completed a funding round led by Trog Hawley Capital, bringing its valuation near 100 million euros. The company raised a high seven-digit amount in equity and debt, and plans to use the funds to improve its online selling platform.MarketScreenerCannabis producer Demecan nears 100-million-euro valuation after fresh funding, source saysDemecan Group, a leading German cannabis producer, has completed a new funding round led by U.S.-based Trog Hawley Capital, bringing its valuation close to 100 million euros. The company raised a high seven-digit sum in equity and debt to enhance its online sales platform and expand operations within Germany's growing medical cannabis market.DemecanDEMECAN successfully closes its funding round and collects a total of EUR 15m in 2022DEMACAN, the only independent vertically-integrated cannabis company in Germany, has successfully closed its funding round, raising a total of EUR 15 million in 2022 from loans and equity financing. The funds will be used to expand production capacity at its Ebersbach facility and prepare for the expected legalization of recreational cannabis. In addition to this expansion, DEMACAN continues to engage in the medical cannabis sector and advance its research and development initiatives.GlobeNewswireLittle Green Pharma Enters Into Agreement to Supply Medicinal Cannabis Products to DEMECANLittle Green Pharma signed a three-year agreement with DEMECAN to sell up to 1,000kg of dried cannabis flower or 48,000 units of medicinal cannabis oil per year. The German market is the largest in the EU, with 240,000 prescriptions expected by end of 2019. First shipments to Germany are expected in the second half of 2020.TechCrunchGerman tech investor leads Series A for Germany’s first medical cannabis startupBerlin startup Demecan raised €7 million in a Series A to expand its medical cannabis production and wholesale operations. It is the only German company permitted to produce medical cannabis, with production capacity of 2,400 kg over four years. The company plans to start production in 2020.